Seven were on mTOR inhibitors before cancer and 2 had graft nephrectomy (one due to renal cell carcinoma and the other due to non-Hodgkin lymphoma within the grafts) with subsequent withdrawal of immunosuppression. Here, MTOR is linked to hereditary clear cell renal cell carcinoma.